May 5, 2026 Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026 Kore.ai Establishes Bay Area Strategic Headquarters to Lead the Next Wave of Enterprise AI